New Molecular Pathway Identified in Age-Related Bone Loss
The PRMT6-SIRT5-HADHA axis regulates bone aging, offering a target for potential therapies against osteoporosis.
Updated on Oct. 31, 2026 in Life Sciences
Live Poll
Do you trust that new medical research will successfully lead to treatments for aging-related conditions?
Researchers have identified the PRMT6-SIRT5-HADHA signaling pathway as a central regulator of bone aging. The study, published on October 31, 2026, demonstrates in mouse models that restoring SIRT5 expression can mitigate bone loss by reducing the accumulation of R-loops.
Why it matters
Understanding this molecular pathway reveals a specific mechanism behind osteoblast senescence, providing a potential therapeutic target for age-related osteoporosis. This research bridges genetic signaling and skeletal health at the cellular level.
Researchers used AAV5, a modified harmless virus used as a delivery vehicle, to overexpress SIRT5 in mice. This intervention successfully restored HADHA protein abundance, which is otherwise diminished in Sirt5-deficient states.
The players
PRMT6-SIRT5-HADHA signaling pathway
A newly identified molecular mechanism that regulates osteoblast aging and skeletal density.
The details
The PRMT6-SIRT5-HADHA axis functions by managing succinylation, a biochemical modification of proteins, and R-loops, which are structures where DNA and RNA hybridize. When PRMT6 or SIRT5 is deficient, multi-site succinylation of the HADHA protein increases, leading to a reduction in protein levels. This deficiency triggers an accumulation of R-loops at transcription start sites, accelerating the senescence of osteoblasts, the cells responsible for bone formation.
Timeline
October 31, 2026: Article publication date.
The Tech Race
This research provides a new molecular target in the competitive effort to develop anti-aging therapeutics for bone health. It marks a departure from traditional calcium-focused treatments by shifting the focus toward specific enzymatic signaling pathways.
This research remains at the laboratory stage and is not currently applicable to human clinical practice. The next milestone will require determining if pharmacological or genetic interventions can safely modulate this pathway in human subjects.
The takeaway
The discovery of the PRMT6-SIRT5-HADHA pathway identifies a specific molecular target for age-related bone decline. Readers should monitor future studies for therapeutic trials targeting SIRT5 or HADHA in humans.
Further reading
For broader trends in skeletal biology and cellular aging, explore our Life Sciences section.
More information
Access the full peer-reviewed research article for detailed methodology and data.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that new medical research will successfully lead to treatments for aging-related conditions?
